Kindeva Drug Delivery (Kindeva), a prominent global player in the realm of drug and device combination products, has disclosed today the appointment of Denis Johnson as its new Chief Operating Officer (COO). In his capacity at Kindeva, Denis will spearhead the company’s global operations, overseeing all advanced manufacturing, research, and development facilities across the United States and the United Kingdom.
As COO, Denis will devote his efforts to global operations, with a particular emphasis on the expansion and inauguration of Kindeva’s new aseptic fill and finish injection site in Bridgeton, Missouri, slated for this year. Additionally, he will champion the company’s initiative to introduce environmentally sustainable propellants in the commercial production of combination products, with Kindeva being the sole Contract Development and Manufacturing Organization (CDMO) capable of employing the low global warming potential propellant 152a in inhalers. Denis brings a wealth of management and production expertise in the life sciences sector, having held significant roles at Biogen, Catalent, Boston Scientific, Teradyne, and Johnson & Johnson. His career commenced in logistics administration and operations for the US Army.
“Denis’ extensive experience in the CDMO landscape and his proven track record in enhancing operational efficiency will be invaluable as Kindeva continues to expand and innovate in drug delivery,” remarked Kindeva CEO Milton Boyer. “His adept leadership and profound market insight will be particularly instrumental in launching Kindeva’s pioneering environmentally sustainable propellant product line, 152a, into the market. Clinical supply is already secured, and we anticipate rolling out the first products utilizing this alternative propellant by 2025. Denis will also concentrate on streamlining production processes, optimizing operational efficacy, and upholding the highest quality and compliance standards across our facilities.”
“Kindeva’s dedication to fostering patient-centered, sustainable drug delivery systems and its remarkable growth trajectory, especially in the past year, are commendable,” expressed Denis. I eagerly anticipate joining the Kindeva team to further elevate operational excellence and implement strategies that ensure the timely provision of life-transforming medications to patients globally.
